Bavarian Nordic beats Q3 revenue expectations
Bavarian Nordic beats Q3 revenue expectations Nov 13 (Reuters) - Danish vaccine maker Bavarian Nordic BAVA.CO reported higher than expected revenue for the third quarter on Friday, boosted by a continued strong performance in its travel health business.
Bavarian's outlook increasingly hinges on whether strong rabies demand proves durable and whether newer products such as Vimkunya can offset volatility in the preparedness-vaccine business.
Q3 revenue came to 1.81 billion Danish crowns ($267.81 million) against year-earlier 1.80 billion
It beat analysts' average estimate of 1.69 billion in a company-provided consensus
Bavarian reiterated the full-year guidance it upgraded in October, driven by higher US rabies vaccine sales
Travel health revenue rose 22% to 1.14 billion crowns against company-provided consensus of 1.02 billion, driven by continued strong RabAvert/Rabipur sales and supported by the continued launch of Vimkunya
($1 = 6.7585 Danish crowns)
(Reporting by Elviira Luoma, editing by Matt Scuffham)
((elviira.luoma@thomsonreuters.com; +48 58 769 66 46;))
Recent news on Bavarian Nordic A/S
See all newsBavarian Nordic beats Q3 revenue expectations on travel health strength (updated)
Bavarian Nordic beats Q3 revenue expectations
Brief: Bavarian Nordic Launches Next Tranche Of Share Buy-Back Program
Brief: Bavarian Nordic CFO Henrik Juuel To Step Down
Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook